arrow
M

Marina Konopleva

montefiore medical center
H指数:130
被引数:7.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Graft-versus-host disease prophylaxis with abatacept plus intermediate dose cyclophosphamide for GVHD prophylaxis after peripheral blood stem transplantation: a single institution study

阿巴西特联合中剂量环磷酰胺预防异基因造血干细胞移植后移植物抗宿主病:一项单中心研究

2026-07-270
PRE
Tagraxofusp, azacitidine, and venetoclax in blastic plasmacytoid dendritic cell neoplasm

Tagraxofusp、azacitidine和venetoclax在 blasts plasmacytoid dendritic cell neoplasm 中的应用

Blood
IF23.1
2026-07-080
OA
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II

TXNRD1下调与tagraxofusp耐药性相关,这在II期临床试验中有所体现,见于 blasts plasmacytoid dendritic cell neoplasms

Leukemia
IF13.4
2026-07-060
OAAI
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia

STAT3降解剂在Venetoclax耐药急性髓系白血病中显示出疗效

Leukemia
IF13.4
2026-02-170
OAAI
Peginterferon alfa-2a, bictegravir-emtricitabine-tenofovir alafenamide, and venetoclax in adult T-cell leukemia/lymphoma

培吉特罗韦alfa-2a、比克替拉韦-恩曲他滨-替诺福韦艾拉酚胺,以及维奈克拉在成人T细胞白血病/淋巴瘤中的应用

Blood
IF23.1
2026-01-010
OAAI
Triterpenoid Exposure and HO-1 Blockade Sensitize Neoplastic Mast Cells Against Midostaurin and Avapritinib

三萜暴露和HO-1阻断使肿瘤性肥大细胞对米多司他汀和阿瓦普利替尼更敏感

Cells
IF5.2
2026-01-010
OA
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

更正:维奈克拉联合FLAG-IDA诱导和巩固治疗新诊断及复发或难治性急性髓系白血病的长期结果

Leukemia
IF13.4
2025-12-100
OAAI
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

DS-1594 menin抑制剂的1/2期研究:在复发/难治性急性白血病中的应用

2025-11-270
OAAI
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

早期造血细胞群内的快速克隆选择预示ivosidenib联合治疗的结局

Blood
IF23.1
2025-11-070
PRE
First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial

一线tagraxofusp治疗可诱导年龄小于50岁的blastic plasmacytoid dendritic cell neoplasm成年患者的持久缓解并延长其生存期:一项2期临床试验的回顾性分析

2025-10-120
OAAI
Quiescent OXPHOS-High Triple-Negative Breast Cancer Cells That Persist After Chemotherapy Depend on BCL-XL for Survival

化疗后存活的静息OXPHOS高表达三阴性乳腺癌细胞依赖BCL-XL维持生存

2025-10-080
OAAI
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia

靶向凋亡的BH3拟似物:改变急性髓系白血病患者的治疗方法

2025-09-010
PRE
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification

评估冰岛筛查、治疗或预防多发性骨髓瘤(iStopMM)模型在多元文化布朗克斯队列中的表现:对未定意义单克隆丙种球蛋白病的风险分层的影响

2025-08-210
OAAI
Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage ambiguous leukemia

维奈克拉联合吉特利替尼在FLT3突变BCL11B-a谱系模糊性白血病的体外模型中是有效的。

Blood
IF23.1
2025-08-180
OA
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax

新诊断IDH突变型AML成人患者接受强化化疗和维奈克拉治疗后的结局

Leukemia
IF13.4
2025-08-140
PRE